JPH08501297A - Nmda受容体媒介性神経障害の防止法 - Google Patents
Nmda受容体媒介性神経障害の防止法Info
- Publication number
- JPH08501297A JPH08501297A JP6507482A JP50748294A JPH08501297A JP H08501297 A JPH08501297 A JP H08501297A JP 6507482 A JP6507482 A JP 6507482A JP 50748294 A JP50748294 A JP 50748294A JP H08501297 A JPH08501297 A JP H08501297A
- Authority
- JP
- Japan
- Prior art keywords
- nmda
- compound
- mammal
- independently
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 哺乳類における非虚血性NMDA受容体の媒介による神経細胞の退化を遅 らせる方法であって、図1に示される式で表される化合物を哺乳類に投与する行 程を含んでおり、この化合物において、R1はアミノ基、R2−R17は互いに無関 係に水素(H)あるいは1−5個の炭素を含む短鎖脂肪族基であり、R4とR10 も(互いに無関係に)ハロゲンあるいはアシル基、あるいはこれらの生理学的に 許容される塩であり、上記退化を遅らせるのに有効な濃度であることを特徴とす る方法。 2. 哺乳類における非虚血性NMDA受容体の媒介による神経細胞の退化を遅 らせる治療方法であって、この治療方法は図1に示される式で表される化合物を 投与する行程を含んでおり、この化合物において、R1はアミノ基、R2−R17は 互いに無関係に水素(H)あるいは1−5個の炭素を含む短鎖脂肪族基であり、 R4とR10も(互いに無関係に)ハロゲンあるいはアシル基、あるいはこれらの 生理学的に許容される塩であり、上記退化を遅らせるのに有効な濃度であること を特徴とする方法。 3. R1がNH2であることを特徴とする請求の範囲第1項あるいは2項に記載 の方法。 4. 上記化合物がアマンタディン(amantadine)であることを特徴 とする請求の範囲第3項に記載の方法。 5. R4がメチル基であることを特徴とする請求の範囲第1項あるいは2項に 記載の方法。 6. R10がメチル基であることを特徴とする請求の範囲第1、2あるいは3項 に記載の方法。 7. R4及びR10がメチル基であることを特徴とする請求の範囲第1あるいは 2項に記載の方法。 8. R1がNH2であることを特徴とする請求の範囲第7項に記載の方法。 9. 上記化合物がメマンチン(memantine)であることを特徴とする 請求の範囲8項に記載の方法。 10. R1が であり、X1とX2が互いに無関係に水素(H)あるいは1−5個の炭素を有する 短鎖脂肪族基であることを特徴とする請求の範囲第1あるいは2項に記載の方法 。 11. X1とX2がそれぞれ水素(H)とCH3であるか、あるいはX1とX2が それぞれCH3と水素(H)であることを特徴とする請求の範囲10に記載の方 法。 12. 上記化合物がレマンタディン(rimantadine)であることを 特徴とする請求の範囲第11項に記載の方法。 13. R4がメチル基であることを特徴とする請求の範囲第10項に記載の方 法。 14. R10がメチル基であることを特徴とする請求の範囲第10項に記載の方 法。 15. R4とR10がメチル基であることを特徴とする請求の範囲第10項に記 載の方法。 16. 上記神経毒性が興奮性アミノ酸によって媒介されることを特徴とする請 求の範囲第1あるいは2項に記載の方法。 17. 上記神経毒性が、グルタミン酸塩(glutamate)、アスパルテ ート(aspartate)、ホモシスチック(homocysteic)酸、 システイン(cysteine)硫酸、システイン酸、キノリネート(quin olinate)、あるいはN−アセチル・アスパチル・グルタメート(asp artyl gulutamate)であることを特徴とする請求の範囲第1あ るいは2項に記載の方法。 18. 上記哺乳類は、非虚血性のアルツハイマー病に患かっていることを特徴 とする請求の範囲第1あるいは2項に記載の方法。 19. 上記哺乳類は、ハンティング舞踏病あるいは 筋萎縮側索硬化症に患か っていることを特徴とする請求の範囲第1あるいは2項に記載の方法。 20. 上記哺乳類は、神経性ラチリスム(neurolathyrism); グアム(Guam)病、olivo−pontocerebellar小脳萎縮 症、高血糖症(非ケトン性)、肝性脳障害、尿毒脳障害、4−ヒドロキシ酪酸性 尿症(4−hydroxybuturic aciduria),MELAS症 候群、レットt症候群、ホモシスチン症、高プロリン症(hyperproli nemia)、及び末梢神経症のいずれかに患かっていることを特徴とする請求 の範囲第1あるいは2項に記載の方法。 21. 上記哺乳類は、長期にわたり非虚血性の神経退化症に患かっていること を特徴とする請求の範囲第1あるいは2項に記載の方法。 22. 上記哺乳類は、中央神経組織損傷に患っていることを特徴とする請求の 範囲第1あるいは2項に記載の方法。 23. 上記哺乳類は、一酸化炭素、鉛、domoic酸中毒に患かっているこ とを特徴とする請求の範囲第1あるいは2項に記載の方法。 24. 候補NMDAチャンネル拮抗質(antagonists)の安全性と 有効性を確認するために予備スクリーニングする方法であって、 a)NMDA−受容体関連のイオンチャンネルの遮断を誘起するために候補物 質が要する時間を査定することと、 b)化合物の投与が停止されたときに、イオンチャンネルの遮断が終了するの に要する時間を査定することと、 c)NMDA興奮性物質が無いきに、NMDAにより媒介された電流を遮断す る化合物の機能を査定することと、 d)MK−801に特有な時間よりも短かく、(a)あるいは(b)の時間を 要する物質と、(c)において実質的にマイナスの結果をもたらし、臨床的に耐 性のある選択的NMDA拮抗質である候補物質を選択することと、 e)化合物がNMDA神経毒性に対して有効であることの確認を含むことを特 徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/939,824 US5334618A (en) | 1991-04-04 | 1992-09-03 | Method of preventing NMDA receptor-mediated neuronal damage |
US07/939,824 | 1992-09-03 | ||
PCT/US1993/008344 WO1994005275A1 (en) | 1992-09-03 | 1993-09-03 | Method of preventing nmda receptor-mediated neuronal damage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005354152A Division JP2006077034A (ja) | 1992-09-03 | 2005-12-07 | Nmda受容体媒介性神経障害の防止薬剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08501297A true JPH08501297A (ja) | 1996-02-13 |
Family
ID=25473800
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6507482A Pending JPH08501297A (ja) | 1992-09-03 | 1993-09-03 | Nmda受容体媒介性神経障害の防止法 |
JP2005354152A Pending JP2006077034A (ja) | 1992-09-03 | 2005-12-07 | Nmda受容体媒介性神経障害の防止薬剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005354152A Pending JP2006077034A (ja) | 1992-09-03 | 2005-12-07 | Nmda受容体媒介性神経障害の防止薬剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5334618A (ja) |
EP (1) | EP0660707B1 (ja) |
JP (2) | JPH08501297A (ja) |
AT (1) | ATE202474T1 (ja) |
AU (1) | AU4847693A (ja) |
CA (1) | CA2143752C (ja) |
DE (1) | DE69330387T2 (ja) |
DK (1) | DK0660707T3 (ja) |
ES (1) | ES2159528T3 (ja) |
GR (1) | GR3036657T3 (ja) |
PT (1) | PT660707E (ja) |
WO (1) | WO1994005275A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535360A (ja) * | 1999-01-26 | 2002-10-22 | バーナリス リサーチ リミテッド | グルタメート作用性伝達における異常を処置するための2−アダマンタンメタンアミン化合物 |
JP2005505548A (ja) * | 2001-08-29 | 2005-02-24 | ユクロ ヨーロピアン コントラクト リサーチ ゲーエムベーハー ウント コー.カーゲー | 神経細胞変性の病気の治療のためのβ−アドレナリン受容体拮抗薬を使用する方法 |
JP2021504303A (ja) * | 2017-11-22 | 2021-02-15 | パノラマ リサーチ,インコーポレイティド | Cns疾患を治療するためのアミノアダマンチルナイトレート化合物およびそれらの使用 |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2714828B1 (fr) * | 1994-01-12 | 1996-02-02 | Rhone Poulenc Rorer Sa | Application du riluzole dans le traitement des maladies mitochondriales. |
US6025369A (en) * | 1996-05-03 | 2000-02-15 | The Board Of Regents Of The University Nebraska | N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
US20060167114A1 (en) * | 1998-03-09 | 2006-07-27 | Louis Shuster | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
US6242456B1 (en) * | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
US20070197651A1 (en) * | 1998-03-09 | 2007-08-23 | Tufts University | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | REDUCTION AGENTS OF A (BETA) 42 |
EP1190708A1 (en) * | 2000-09-21 | 2002-03-27 | Tinnitus Forschungs- und Entwicklungs GmbH | Medical use of substances |
EP1190711A1 (en) * | 2000-09-21 | 2002-03-27 | Tinnitus Forschungs- und Entwicklungs GmbH | Treatment of diseases with adamantane derivatives |
EP1201234A3 (en) * | 2000-09-21 | 2003-03-12 | Tinnitus Forschungs- und Entwicklungs GmbH | Treatment of diseases with adamantane derivates |
MXPA03005130A (es) * | 2000-12-07 | 2004-12-06 | Neuromolecular Inc | Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda. |
EP1852113A3 (en) * | 2000-12-07 | 2008-03-12 | Neuromolecular Inc. | Methods for treating neuropsychiatric disorders with NMDA receptors antagonists |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
GB0202161D0 (en) * | 2002-01-30 | 2002-03-20 | Vernalis Res Ltd | Chemical compounds V |
AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
US8557855B2 (en) * | 2002-07-03 | 2013-10-15 | Allergan, Inc. | Methods of using ryanodine antagonists in treating neural injury |
US20050148673A1 (en) * | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
KR100852834B1 (ko) | 2002-10-24 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료 |
EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
WO2005000216A2 (en) | 2003-05-27 | 2005-01-06 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
EP1651195A4 (en) * | 2003-07-11 | 2007-10-03 | Myriad Genetics Inc | PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE |
AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
DE602005024511D1 (de) * | 2004-01-05 | 2010-12-16 | Merz Pharma Gmbh & Co Kgaa | Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer |
WO2005072705A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
ES2483126T3 (es) | 2004-06-17 | 2014-08-05 | Merz Pharma Gmbh & Co. Kgaa | Formulaciones de formas de dosificación de neramexano |
CA2569015A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
CA2618985A1 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
CN100351225C (zh) * | 2004-10-28 | 2007-11-28 | 中国医学科学院医药生物技术研究所 | 一组金刚烷胺类衍生物及其合成方法和作为神经元损伤保护剂的应用 |
EP1827385B1 (en) | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
US20080009546A1 (en) * | 2005-05-06 | 2008-01-10 | Chevron U.S.A. Inc. | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders |
CA2607600A1 (en) * | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
EP2040676A2 (en) * | 2006-07-06 | 2009-04-01 | Forest Laboratories, Inc. | Orally dissolving formulations of memantine |
EP2046119A2 (en) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
WO2009151498A2 (en) * | 2008-03-28 | 2009-12-17 | Forest Laboratories Holdings Limited | Memantine formulations |
EP2138173A1 (en) | 2008-06-26 | 2009-12-30 | Merz Pharma GmbH & Co.KGaA | Pharmaceutical compositions comprising aminoadamantane derivatives |
EP3132793A1 (en) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
MX2012008514A (es) | 2010-01-27 | 2012-08-17 | Takeda Pharmaceutical | Compuesto para suministrar transtorno de nervio periferico inducido por agente anticancerigeno. |
JP5562716B2 (ja) * | 2010-05-12 | 2014-07-30 | 花王株式会社 | 電位依存性カチオンチャネル抑制剤 |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328251A (en) * | 1965-12-30 | 1967-06-27 | Du Pont | Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives |
US3391142A (en) * | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
US3456057A (en) * | 1968-06-28 | 1969-07-15 | Du Pont | Pharmaceutical compositions and methods utilizing 3-aminotricyclo(4.3.1.1**3.8)undecanes |
CA974518A (en) * | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
IL53441A0 (en) * | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
US4148896A (en) * | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
US4351847A (en) * | 1981-06-26 | 1982-09-28 | Pennwalt Corporation | Antiviral alpha, alpha-dialkyl adamantylethylamines |
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
US4837218A (en) * | 1987-10-23 | 1989-06-06 | Washington University | Alkylated bicycloalkaneamines for treatment of neurotoxic injury |
ATE94384T1 (de) * | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
DE3940410A1 (de) * | 1989-12-04 | 1991-06-06 | Schering Ag | Neue verwendung von nmda-rezeptor-antagonisten |
WO1992017168A1 (en) * | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
US5124319A (en) * | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
-
1992
- 1992-09-03 US US07/939,824 patent/US5334618A/en not_active Expired - Lifetime
-
1993
- 1993-09-03 EP EP93921355A patent/EP0660707B1/en not_active Expired - Lifetime
- 1993-09-03 AU AU48476/93A patent/AU4847693A/en not_active Abandoned
- 1993-09-03 JP JP6507482A patent/JPH08501297A/ja active Pending
- 1993-09-03 AT AT93921355T patent/ATE202474T1/de active
- 1993-09-03 DE DE69330387T patent/DE69330387T2/de not_active Expired - Lifetime
- 1993-09-03 CA CA002143752A patent/CA2143752C/en not_active Expired - Lifetime
- 1993-09-03 PT PT93921355T patent/PT660707E/pt unknown
- 1993-09-03 DK DK93921355T patent/DK0660707T3/da active
- 1993-09-03 WO PCT/US1993/008344 patent/WO1994005275A1/en active IP Right Grant
- 1993-09-03 ES ES93921355T patent/ES2159528T3/es not_active Expired - Lifetime
-
2001
- 2001-09-18 GR GR20010401515T patent/GR3036657T3/el unknown
-
2005
- 2005-12-07 JP JP2005354152A patent/JP2006077034A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535360A (ja) * | 1999-01-26 | 2002-10-22 | バーナリス リサーチ リミテッド | グルタメート作用性伝達における異常を処置するための2−アダマンタンメタンアミン化合物 |
JP2005505548A (ja) * | 2001-08-29 | 2005-02-24 | ユクロ ヨーロピアン コントラクト リサーチ ゲーエムベーハー ウント コー.カーゲー | 神経細胞変性の病気の治療のためのβ−アドレナリン受容体拮抗薬を使用する方法 |
JP2021504303A (ja) * | 2017-11-22 | 2021-02-15 | パノラマ リサーチ,インコーポレイティド | Cns疾患を治療するためのアミノアダマンチルナイトレート化合物およびそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
DE69330387D1 (de) | 2001-08-02 |
DE69330387T2 (de) | 2002-05-16 |
EP0660707A4 (en) | 1998-05-13 |
PT660707E (pt) | 2001-11-30 |
EP0660707A1 (en) | 1995-07-05 |
GR3036657T3 (en) | 2001-12-31 |
ES2159528T3 (es) | 2001-10-16 |
AU4847693A (en) | 1994-03-29 |
WO1994005275A1 (en) | 1994-03-17 |
EP0660707B1 (en) | 2001-06-27 |
ATE202474T1 (de) | 2001-07-15 |
JP2006077034A (ja) | 2006-03-23 |
CA2143752A1 (en) | 1994-03-17 |
DK0660707T3 (da) | 2001-10-01 |
US5334618A (en) | 1994-08-02 |
CA2143752C (en) | 2008-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08501297A (ja) | Nmda受容体媒介性神経障害の防止法 | |
US5614560A (en) | Method of preventing NMDA receptor-mediated neuronal damage | |
WO1994005275A9 (en) | Method of preventing nmda receptor-mediated neuronal damage | |
DE69930552T2 (de) | Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen | |
US20180250244A1 (en) | Exo-s-mecamylamine formulation and use in treatment | |
JP5363152B2 (ja) | グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置 | |
JP2008169223A (ja) | 視神経炎の治療 | |
CN106456583B (zh) | 用于治疗神经障碍的巴氯芬、阿坎酸和中链甘油三酯的组合 | |
KR20020025221A (ko) | 트라마돌 화합물 및 항경련 약물을 포함하는 조성물 | |
JP2009501224A (ja) | 神経保護の方法 | |
US6562365B2 (en) | Methods employing R(−)-desmethylselegiline | |
ZA200007174B (en) | Method for the treatment of insomnia. | |
US5474990A (en) | Barbiturates as safening agents in conjunction with NMDA antagonists | |
WO2003024443A1 (en) | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors | |
KR20030053475A (ko) | 5-ht3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물 | |
US6335371B1 (en) | Method for inducing cognition enhancement | |
WO1992017168A1 (en) | Method of preventing nmda receptor-mediated neuronal damage | |
JPH03209335A (ja) | 慢性神経変質性疾病予防薬の製法及び作用量のnmda―受容体複合体の拮抗剤を含有する薬剤 | |
EP0414568A2 (en) | Use of anticholinergic compounds for protecting the central nervous system against cholinergic neurotoxins | |
KR20050121236A (ko) | 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도 | |
US6335372B1 (en) | Treatment of obsessive compulsive disorder | |
DE19902924A1 (de) | Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen | |
AU705888B2 (en) | Method of preventing NMDA receptor-mediated neuronal damage | |
Banday et al. | Gabapentin: A pharmacotherapeutic panacea | |
JP7257091B2 (ja) | 認知症の治療及び予防薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040426 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20040426 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040727 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051207 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060105 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061016 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061020 |